Oncology News Central Peer-Spectives

From SABCS ’21: Neoadjuvant Immunotherapy and the Use of the 21-Gene Signature Test

Lajos Pusztai, MD, and Robert Figlin, MD, discuss the practicality of neoadjuvant I-O as demonstrated in KEYNOTE-522 and the application of the Oncotype DX 21-gene signature test in the RxPONDER study, both presented at the 2021 San Antonio Breast Cancer Symposium.

Targeted Therapy and Venclexta Combinations for AML and a Look Ahead to ASH ’21

Naval Daver, MD, and Robert Figlin, MD, discuss FLT3, TP53, and venetoclax combinations in the management of AML patients and what to look forward to at ASH 2021.  

After CodeBreaK100:

Kathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the importance of the KRAS-targeted drug, sotorasib, in the treatment of non-small cell lung cancer. Kathryn Arbour, MD, joins host Robert Figlin, MD, to discuss the role next-generation sequencing plays in lung cancer care, the responses seen with the KRAS-targeted drug, sotorasib, in CodeBreaK100, and what optimal use of the drug will look like down the road.

ESMO ’21: The ARCHES Study and Progress in Metastatic (and Non-Metastatic) Hormone-Sensitive Prostate Cancer

Andrew Armstrong, MD and Robert Figlin, MD discuss the ARCHES study investigating the role of enzalutamide in metastatic hormone-sensitive prostate cancer, followed by a discussion of the latest treatment trends in non-metastatic hormone-sensitive prostate cancer.

Recent Clinical Progress in Ovarian Cancer

Robert Coleman, MD and Robert Figlin, MD, discuss the evolving role of bevacizumab in ovarian cancer, recently presented clinical studies such as BOOST and EFFORT, and the challenge of treating the PARP-refractory setting in advanced ovarian cancer.

Post-EHA 2021: Latest Treatment Trends in the Management of Chronic Lymphocytic Leukemia (CLL)

Non-Small Cell Lung Cancer Clinical Highlights From ASCO 2021

Jeffrey Crawford, MD, and Robert Figlin, MD, discuss highlights from ASCO ’21 including immunotherapy, adjuvant and neoadjuvant therapy ie IMpower010 and Checkmate-816, and finish up with a discussion regarding molecular tests, MYLUNG, and NGS as it applies to NSCLC.

Colorectal Cancer Clinical Highlights From ASCO 2021

Andrew Hendifar, MD, and Robert Figlin, MD, discuss highlights from the 2021 ASCO annual meeting, including immunotherapy in MSI-H/dMMR metastatic CRC patients, looking for DEEPER responses in RAS-wild type tumors, the need for testing for HER2+ CRC patients, and liquid biopsy and the CHRONOS trial.

Breast Cancer Clinical Highlights from ASCO 2021

Erika Hamilton, MD, of the Sarah Cannon Research Institute, and Robert Figlin, MD, of Cedars-Sinai Medical Center, discuss breast cancer research from the 2021 annual meeting of the American Society of Clinical Oncology, including adjuvant and neo-adjuvant breast cancer, metastatic disease, the role of CDK 4/6 inhibitors and PARP inhibitors, the potential of SERDs, and a negative study.

Non Small Cell Lung Cancer (NSCLC) – Robert Figlin, MD, and Melissa Johnson, MD, discuss the different driver mutations in non small cell lung cancer ...

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Program Director, Lung Cancer Research, Sarah Cannon Research Institute, discuss the different driver mutations in Non Small Cell Lung Cancer (NSCLC) and how to use them to guide treatment